213 related articles for article (PubMed ID: 22495699)
21. Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer.
Han SW; Cha Y; Paquet A; Huang W; Weidler J; Lie Y; Sherwood T; Bates M; Haddad M; Park IH; Oh DY; Lee KS; Im SA; Bang YJ; Ro J; Kim TY
PLoS One; 2012; 7(7):e39943. PubMed ID: 22848366
[TBL] [Abstract][Full Text] [Related]
22. Metastatic breast cancer treated with lapatinib with a prolonged benefit: a case report and a review of therapeutic options available.
Bianchi GV; Duca M; Sica L; Mariani G
Tumori; 2013; 99(6):269e-72e. PubMed ID: 24503801
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.
Saura C; Garcia-Saenz JA; Xu B; Harb W; Moroose R; Pluard T; Cortés J; Kiger C; Germa C; Wang K; Martin M; Baselga J; Kim SB
J Clin Oncol; 2014 Nov; 32(32):3626-33. PubMed ID: 25287822
[TBL] [Abstract][Full Text] [Related]
24. 18FDG-PET for early prediction of complete response to lapatinib and capecitabine in HER2-positive metastatic breast cancer: a case report.
Riccardi F; Mocerino C; Barbato C; Vitale MG; Carrillo G; Trunfio M; Minelli S; Cartenì G
Tumori; 2013; 99(6):257e-60e. PubMed ID: 24503798
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes.
Ishida T; Kiba T; Takeda M; Matsuyama K; Teramukai S; Ishiwata R; Masuda N; Takatsuka Y; Noguchi S; Ishioka C; Fukushima M; Ohuchi N
Cancer Chemother Pharmacol; 2009 Jul; 64(2):361-9. PubMed ID: 19082596
[TBL] [Abstract][Full Text] [Related]
26. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.
Bachelot T; Romieu G; Campone M; Diéras V; Cropet C; Dalenc F; Jimenez M; Le Rhun E; Pierga JY; Gonçalves A; Leheurteur M; Domont J; Gutierrez M; Curé H; Ferrero JM; Labbe-Devilliers C
Lancet Oncol; 2013 Jan; 14(1):64-71. PubMed ID: 23122784
[TBL] [Abstract][Full Text] [Related]
27. Trastuzumab-containing regimens for metastatic breast cancer.
Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
[TBL] [Abstract][Full Text] [Related]
28. Rapid tumor shrinkage with lapatinib plus capecitabine in a patient with massive liver involvement.
Giotta F; Latorre A; Cramarossa A; Simone G; Florio C; Oliva S; Lorusso V
Tumori; 2013; 99(6):278e-81e. PubMed ID: 24503803
[TBL] [Abstract][Full Text] [Related]
29. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience.
Sutherland S; Ashley S; Miles D; Chan S; Wardley A; Davidson N; Bhatti R; Shehata M; Nouras H; Camburn T; Johnston SR
Br J Cancer; 2010 Mar; 102(6):995-1002. PubMed ID: 20179708
[TBL] [Abstract][Full Text] [Related]
30. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
Martin M; Bonneterre J; Geyer CE; Ito Y; Ro J; Lang I; Kim SB; Germa C; Vermette J; Wang K; Wang K; Awada A
Eur J Cancer; 2013 Dec; 49(18):3763-72. PubMed ID: 23953056
[TBL] [Abstract][Full Text] [Related]
31. Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients.
Xu BH; Jiang ZF; Chua D; Shao ZM; Luo RC; Wang XJ; Liu DG; Yeo W; Yu SY; Newstat B; Preston A; Martin AM; Chi HD; Wang L
Chin J Cancer; 2011 May; 30(5):327-35. PubMed ID: 21527065
[TBL] [Abstract][Full Text] [Related]
32. Lapatinib for the treatment of HER2-overexpressing breast cancer.
Jones J; Takeda A; Picot J; von Keyserlingk C; Clegg A
Health Technol Assess; 2009 Oct; 13 Suppl 3():1-6. PubMed ID: 19846022
[TBL] [Abstract][Full Text] [Related]
33. Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results.
Michalaki V; Fotiou S; Gennatas S; Gennatas C
Anticancer Res; 2010 Jul; 30(7):3051-4. PubMed ID: 20683054
[TBL] [Abstract][Full Text] [Related]
34. Lapatinib: a review of its use in the treatment of HER2-overexpressing, trastuzumab-refractory, advanced or metastatic breast cancer.
Frampton JE
Drugs; 2009 Oct; 69(15):2125-48. PubMed ID: 19791830
[TBL] [Abstract][Full Text] [Related]
35. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial.
Cameron D; Casey M; Oliva C; Newstat B; Imwalle B; Geyer CE
Oncologist; 2010; 15(9):924-34. PubMed ID: 20736298
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
[TBL] [Abstract][Full Text] [Related]
37. An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer.
Capri G; Chang J; Chen SC; Conte P; Cwiertka K; Jerusalem G; Jiang Z; Johnston S; Kaufman B; Link J; Ro J; Schütte J; Oliva C; Parikh R; Preston A; Rosenlund J; Selzer M; Zembryki D; De Placido S
Ann Oncol; 2010 Mar; 21(3):474-480. PubMed ID: 19815649
[TBL] [Abstract][Full Text] [Related]
38. Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.
Ma F; Ouyang Q; Li W; Jiang Z; Tong Z; Liu Y; Li H; Yu S; Feng J; Wang S; Hu X; Zou J; Zhu X; Xu B
J Clin Oncol; 2019 Oct; 37(29):2610-2619. PubMed ID: 31430226
[TBL] [Abstract][Full Text] [Related]
39. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.
Bartsch R; Wenzel C; Altorjai G; Pluschnig U; Rudas M; Mader RM; Gnant M; Zielinski CC; Steger GG
J Clin Oncol; 2007 Sep; 25(25):3853-8. PubMed ID: 17679724
[TBL] [Abstract][Full Text] [Related]
40. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Lorenzen S; Riera Knorrenschild J; Haag GM; Pohl M; Thuss-Patience P; Bassermann F; Helbig U; Weißinger F; Schnoy E; Becker K; Stocker G; Rüschoff J; Eisenmenger A; Karapanagiotou-Schenkel I; Lordick F
Eur J Cancer; 2015 Mar; 51(5):569-76. PubMed ID: 25694417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]